Oric Pharmaceuticals, Inc. — Director's Dealing 2020

Apr 24, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2020-04-23

Reporting Person: COLUMN GROUP II, LP (10% Owner)
Reporting Person: Column Group II GP, LP (10% Owner, General Partner)
Reporting Person: GOEDDEL DAVID V (10% Owner, Managing Partner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	75000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (3500000)		Direct
Series B Preferred Stock	$		Common Stock (625000)		Direct
Series C Preferred Stock	$		Common Stock (416666)		Direct
Series D Preferred Stock	$		Common Stock (151515)		Direct

Footnotes

F1: The securities are directly held by The Column Group II, LP ("TCG II LP"), and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual managing partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F2: The number of shares of Common Stock reflects a 1-for-4 reverse stock split of the Issuer's Common Stock and Preferred Stock which became effective April 21, 2020. Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock, for no additional consideration, and has no expiration date.